Principal Scientist
Bristol-Myers Squibb Company
Ms. Xiling Yuan is a principal scientist in Translational Sciences and Diagnostics group at Bristol Myers Squibb. She serves as a clinical biomarker immunoassays technical lead to deliver key target engagement and pharmacodynamic biomarker assays for early- and late-stage clinical programs. She has developed and validated ligand binding assays for many soluble targets such as sPD-1, sOX40, sTIM-3, sMICA and free myostatin and deliver decisional data sets. She manages outsourced biomarker immunoassays and is responsible for assessment and selection of CRO, troubleshooting, review and approval of bioanalytical reports. She is highly experienced in various advanced technologies including ultra-high sensitive, multiplexing and diagnostic platforms. She enjoys collaboration, problem solving and data analysis. Prior to this role, she was a member of the metabolic disorders and biochemistry departments of Merck for fifteen years. She developed numerous biochemical and cell-based assays for oncology and diabetes discovery programs and had experience in large scale DNA sequencing.
Xiling obtained her BS in Chemistry from Sichuan University in China and her MS in Biochemistry from the University of Oklahoma where she worked in the Advanced Center for Genome Technology. She can be reached at Xiling.Yuan@bms.com.